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Resource table

  --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  Unique stem cell line identifier        TRNDi002-B

  Alternative name(s) of stem cell line   HT519B

  Institution                             National Institutes of Health, National Center for Advancing Translational Sciences, Bethesda, Maryland, USA

  Contact information of distributor      Dr. Wei Zheng, <Wei.Zheng@nih.gov>

  Type of cell line                       iPSC

  Origin                                  Human

  Additional origin info                  Age: 10-year-old\
                                          Sex: Male\
                                          Ethnicity: Caucasian

  Cell Source                             Skin fibroblasts

  Clonality                               Clonal

  Method of reprogramming                 Integration-free Sendai viral vectors

  Genetic modification                    NO

  Type of modification                    N/A

  Associated disease                      NGLY1 Deficiency

  Gene/locus                              NGLY1^Q208X^; NGLY1^G310G^

  Method of modification                  N/A

  Name of transgene or resistance         N/A

  Inducible/constitutive system           N/A

  Date archived/stock date                04-27-2018

  Cell line repository/bank               Human Pluripotent Stem Cell Registry <https://hpscreg.eu/cell-line/TRNDi002-B>

  Ethical approval                        NIGMS Informed Consent Form was obtained from patient at time of sample submission. Confidentiality Certificate: CC-GM-15-004
  --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------

Resource utility {#S1}
================

This hiPSC line is a useful tool for studies of disease phenotype, disease pathophysiology, and use as a cell-based disease model for drug development to treat patients with NGLY 1 deficiency.

Resource details {#S2}
================

NGLY1 deficiency or NGLY1-congenital disorder of deglycosylation is a rare autosomal recessive disorder caused by mutations in the *NGLY1* gene, which encodes N-glycanase 1. It cleaves N-linked glycans from glycoproteins. Deficiency in N-glycanase 1 results in malfunctions in deglycosylation of N-glycosylated proteins. Because protein glycosylation and deglycosylation play an important role in post-translational modification of proteins, deficiency of this enzyme can cause protein misfolding and aggregation in the endoplasmic reticulum and cytosol, as well as proteasome dysfunction due to defective processing of Nrf1. The typical features of NGLY1 deficiency include developmental delay or intellectual disability of varying degrees, lack of tear production, elevated liver transaminases, and a complex movement disorder ([@R3]; [@R4]; [@R5]).

In this study, a human induced pluripotent stem cell line was established from skin fibroblasts of a 10-year-old male patient (GM25344, Coriell Institute) carrying compound heterozygous mutations of a p. Q208X variant (c.622C \> T) in exon 4 and a p.G310G variant (c.930C \> T) in exon 6 of the *NGLY1* gene ([Table 1](#T2){ref-type="table"}). This subject is also found to be heterozygous for a c.4060 A \> T mutation (Thr1354Ser) in the CACNA1S gene based on the information released by Coriell Institute, which might represent one of the risk factors for increased susceptibility to malignant hyperthermia (MH) ([@R1]). To generate the iPS cells, the non-integrating CytoTune-Sendai viral vector kit (A16517, Thermo Fisher Scientific) containing OCT3/4, KLF4, SOX2 and C-MYC pluripotency transcription factors was employed to transduce the patient fibroblasts using the method described previously ([@R2]). The iPSC line named TRNDi002-B was generated from the patient fibroblasts. The mutations (c.622C \> T and C.930C \> T) of the *NGLY1* gene described by Coriell Institute were confirmed in the TRNDi002-B iPSC line by Sanger sequencing of the PCR product harboring the single nucleotide variation (SNV) ([Fig. 1D](#F1){ref-type="fig"}). The patient iPS cells exhibited a classical embryonic stem cell morphology ([Fig. 1A](#F1){ref-type="fig"}) and normal karyotype (46, XY), as confirmed by the G-banded karyotyping at passage 11 ([Fig. 1C](#F1){ref-type="fig"}), expressed the major pluripotent protein markers of NANOG, SOX2, OCT4, SSEA4 and TRA-1-60 ([Fig. 1A, B](#F1){ref-type="fig"}) evidenced by both immunofluorescence staining and flow cytometry analysis. Sendai virus vector (SeV) clearance was detected with reverse transcription polymerase chain reaction (RT-PCR) using SeV-specific primers, the vector disappeared by passage 15 ([Fig. 1E](#F1){ref-type="fig"}). This iPSC line was not contaminated with mycoplasma ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}) and were authenticated using STR DNA profiling analysis, which demonstrated matching genotypes at all 18 loci examined (information available with the authors). Furthermore, the pluripotency of this iPS cell line was confirmed by the teratoma formation experiment that exhibited its ability to differentiate into cells of all three germ layers (Ectoderm, neural tube; Mesoderm, cartilage; Endoderm, gut) *in vivo* ([Fig. 1F](#F1){ref-type="fig"}).

Materials and methods {#S3}
=====================

Cell culture {#S4}
------------

Patient skin fibroblasts were purchased from Coriell Cell Repositories (GM25344) and cultured in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin in a humidified incubator with 5% CO~2~ at 37 °C. Human iPS cells were cultured in StemFlex medium (Thermo Fisher) on Matrigel (Corning, 354277)-coated plates at 37 °C in humidified air with 5% CO~2~ and 5% O~2~. The cells were passaged with 0.5 mM Ethylenediaminetetraacetic acid (EDTA) at generally 1:6 ratio when they reach 80% confluency.

Reprogramming of human skin fibroblasts {#S5}
---------------------------------------

Patient fibroblasts were reprogrammed into iPS cells using the non-integrating Sendai virus technology following the method described previously ([@R2]).

Genome analysis {#S6}
---------------

The genome analysis of variants in NGLY1 was conducted through Applied StemCell (Milpitas, California, USA). Briefly, genomic DNA was extracted from hiPSC line TRNDi002-B using QuickExtract™ DNA Extraction Solution (Lucigen) followed by PCR amplification using MyTaq™ Red Mix (Bioline, Taunton, MA). Amplifications were carried out on T00 Thermal Cycler from Bio-Rad (\#1861096) using the following program: 95 °C, 2 mins; 35 cycles of \[95 °C, 15 s; 60 °C, 15 s; 72 °C, various length depending on size of amplicon\], 72 °C 5 mins; 4 °C, indefinite. Genotyping of the compound heterozygous for a p. Q208X variant (c.622C \> T) in exon 4 and a p.G310G variant (c.930C \> T) in exon 6 of the *NGLY1* gene were performed using Sanger sequencing analysis. The specific primers for gene amplification and sequencing are listed in [Table 2](#T3){ref-type="table"}.

Immunocytochemistry {#S7}
-------------------

For immunofluorescence staining, patient iPSCs were fixed in 4% paraformaldehyde for 15 mins, rinsed with DPBS, and permeabilized with 0.3% Triton X-100 in DPBS for 15 mins. The cells were incubated with the Image-iT™ FX signal enhancer (ThermoFisher Scientific) for 40 mins at room temperature in a humidified environment and then followed by incubation individually with primary antibodies including SOX2, OCT4, NANOG, SSEA4 and TRA-1-60, diluted in the Image-iT™ FX signal enhancer blocking buffer, for overnight at 4 °C. After washing with DPBS, a corresponding secondary antibody conjugated with Alexa Fluor 488 or Alex Fluor 594 was added to the cells and incubated for 1 h at room temperature (Antibodies used are listed in [Table 2](#T3){ref-type="table"}). Cells were then stained with Hoechst 33342 for 15 mins after a wash and imaged using an INCell Analyzer 2200 imaging system (GE Healthcare) with 20× objective lens and Texas Red, FITC and DAPI filter sets.

Flow cytometry analysis {#S8}
-----------------------

The iPSCs were harvested using TrypLE Express Enzyme (ThermoFisher Scientific). Cells were fixed with 4% paraformaldehyde for 10 mins at room temperature and then washed with DPBS. Before fluorescence-activated cell sorting analysis, cells were permeabilized with 0.2% Tween-20 in DPBS for 10 mins at room temperature and stained with fluorophore conjugated antibodies for 1 h at 4 °C on a shaker (Antibodies used are listed in [Table 2](#T3){ref-type="table"}). Cells were then analyzed on a BD Accuri™ C6 FlowCytometry system (BD Biosciences).

G-banding karyotype {#S9}
-------------------

The G-banding karyotype analysis was conducted at WiCell Research Institute (Madison, WI, USA). A total of 20 randomly selected metaphases were analyzed by G-banding for each cell line.

Short tandem repeat (STR) analysis {#S10}
----------------------------------

Patient fibroblasts and derived iPSC lines were sent to the Johns Hopkins University Genetic Resources Core Facility for STR DNA profile analysis using a Promega PowerPlex 18D Kit. The PCR product was electrophoresed on an ABI Prism^®^ 3730x1 Genetic Analyzer and data was analyzed using GeneMapper^®^ v 4.0 software (Applied Biosystems).

Mycoplasma detection {#S11}
--------------------

Mycoplasma testing was performed and analyzed using the Lonza MycoAlert kit following the instructions from the company. Ratio B/A \> 1.2 indicates mycoplasma positive; 0.9--1.2 Result indicates ambiguous; \< 0.9 indicates mycoplasma negative.

Sendai virus detection {#S12}
----------------------

Total RNA was extracted using RNeasy Plus Mini Kit (Qiagen). Human fibroblasts (GM05659, Coriell Institute) after transfection with Sendai virus for 4 days was used as the positive control. 1 μg of RNA was reverse transcribed into cDNA with Superscript™ III First-Strand Synthesis SuperMix kit and PCR was performed using Platinum II Hot- Start PCR Master Mix (ThermoFisher Scientific) and the amplifications were carried out using the following program: 94 °C, 2 mins; 30 cycles of 94 °C, 15 s, 60 °C, 15 s and 68 °C, 15 s on Mastercycler pro S (Eppendorf) with the primers listed in [Table 2](#T3){ref-type="table"}. The products were then loaded to the *E*-Gel^®^ 1.2% with SYBR Safe™ gel, and imaged by G: Box Chemi-XX6 gel doc system (Syngene, Frederick, MD).

Teratoma formation assay {#S13}
------------------------

Patient iPSCs cultured in 6-well plates were dissociated with DPBS containing 0.5 mM EDTA, and approximately 1 × 10^7^ dissociated cells were resuspended in 400 μl culture medium supplied with 25mM HEPES (pH 7.4) and stored on ice. Then, 50% volume (200 μl) of cold Matrigel (Corning, 354277) was added and mixed with the cells. The mixture was injected subcutaneously into NSG mice (JAX No. 005557) at 150 μl per injection site. Visible tumors were removed 6--8 weeks post injection, and were immediately fixed in 10% Neutral Buffered Formalin. The fixed tumors were embedded in paraffin and stained with hematoxylin and eosin.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2018.101362>.

Supplementary Material {#SM1}
======================
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![Characterization of TRNDi002-B iPSC line.\
**A)** Left: Phase contrast imaging of TRNDi002-B colonies grown on Matrigel at passage 10. Right: Representative immunofluorescent micrographs of iPSCs positive for stem cell markers: SOX2, OCT4, TRA-1-60, NANOG, and SSEA4. Nucleus is labelled with Hoechst (in blue). **B)** Flow cytometry analysis of pluripotency protein markers: TRA-1-60, NANOG and SSEA4. **C)** Cytogenetic analysis showing a normal karyotype (46, XY). **D)** Detection of compound heterozygous of a p.Q208X variant (c.622C \> T) in exon 4 and a p.G310G (c.930C \> T) in exon 6 of the NGLY1 gene. E) RT-PCR verification of the clearance of Sendai virus from the reprogrammed cells. Sendai virus vector transduced fibroblasts was used as positive control. **F)** Pathological analysis of a teratoma from TRNDi002-B iPSC, showing a normal ectodermal, endodermal and mesodermal differentiation.](nihms-1521107-f0001){#F1}

###### 

Characterization and validation.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification                      Test                                   Result                                                               Data
  ----------------------------------- -------------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------
  Morphology                          Photography                            Normal                                                               [Fig. 1](#F1){ref-type="fig"} Panel A

  Phenotype                           Immunocytochemistry                    SOX2, OCT4, NANOG, SSEA-4, TRA-1-60                                  [Fig. 1](#F1){ref-type="fig"} Panel A

                                      Flow cytometry                         TRA-1-60 (87.5%); NANOG (92.1%); SSEA-4 (99.9%)                      [Fig. 1](#F1){ref-type="fig"} Panel B

  Genotype                            Karyotype (G-banding) and resolution   46XY Resolution: 350--400                                            [Fig. 1](#F1){ref-type="fig"} Panel C

  Identity                            Microsatellite PCR (mPCR) OR           Not performed                                                        N/A

                                      STR analysis                           18 sites tested, all sites matched                                   Available with the authors

  Mutation analysis (IF APPLICABLE)   Sequencing                             Compound heterozygous mutation of NGLY1                              [Fig. 1](#F1){ref-type="fig"} Panel D

                                      Southern Blot OR WGS                   N/A                                                                  N/A

  Microbiology and virology           Mycoplasma                             Mycoplasma testing by luminescence. Negative                         [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}

  Differentiation potential           Teratoma formation                     Teratoma with three germlayers formation. Ectoderm (neural tube);\   [Fig. 1](#F1){ref-type="fig"} Panel F
                                                                             Mesoderm (cartilage); Endoderm (gut)                                 

  Donor screening (OPTIONAL)          HIV 1 + 2 Hepatitis B, Hepatitis C     N/A                                                                  N/A

  Genotype additional info            Blood group genotyping                 N/A                                                                  N/A

   (OPTIONAL)                         HLA tissue typing                      N/A                                                                  N/A
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Reagents details.

  Antibodies used for immunocytochemistry/flow-cytometry                                                       
  -------------------------------------------------------- ------------------------------------------ -------- --------------------------------------------------------
  Pluripotency markers                                     Mouse anti-SOX2                            1:50     R & D systems, Cat\# MAB2018, RRID: AB_358009
  Pluripotency markers                                     Rabbit anti-NANOG                          1:400    Cell signaling, Cat\# 4903, RRID: AB_10559205
  Pluripotency markers                                     Rabbit anti-OCT4                           1:400    Thermo Fisher, Cat\# A13998, RRID: AB_2534182
  Pluripotency markers                                     Mouse anti-SSEA4                           1:1000   Cell signaling, Cat\# 4755, RRID: AB_1264259
  Pluripotency markers                                     Mouse anti-TRA-1-60- Alexa Fluor 488       1:10     BD Biosciences, Cat\# 560173, RRID: AB_1645379
  Secondary antibodies                                     Donkey anti-Mouse IgG (Alexa Fluor 488)    1:400    Thermo Fischer, Cat\# A21202, RRID: AB_141607
  Secondary antibodies                                     Donkey anti-Rabbit IgG (Alexa Fluor 594)   1:400    Thermo Fischer, Cat\# A21207, RRID: AB_141637
  Flow cytometry antibodies                                Anti-Tra-1-60-DyLight 488                  1:50     Thermo Fischer, Cat\# MA1--023-D488X, RRID: AB_2536700
  Flow cytometry antibodies                                Anti-Nanog-Alexa Fluor 488                 1:50     Millipore, Cat\# FCABS352A4, RRID: AB_10807973
  Flow cytometry antibodies                                anti-SSEA-4-Alexa Fluor 488                1:50     Thermo Fischer, Cat\# 53--8843-41, RRID: AB_10597752
  Flow cytometry antibodies                                Mouse-IgM-DyLight 488                      1:50     Thermo Fischer, Cat\# MA1--194-D488, RRID: AB_2536969
  Flow cytometry antibodies                                Rabbit IgG-Alexa Fluor 488                 1:50     Cell Signaling, Cat\# 4340S, RRID: AB_10694568
  Flow cytometry antibodies                                Mouse IgG3-FITC                            1:50     Thermo Fischer, Cat\# 11--4742-42, RRID: AB_2043894
                                                                                                               
